This was the stock's second consecutive day of losses.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

SCHD underperformed the S&P 500 in 2025 but remains highly attractive due to its strong risk-reward profile and dividend ...

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

The attorney general is purging the Justice Department of employees connected to the Jan. 6 prosecutions, and the ...

International companies are increasingly inking licensing deals with China biotechs as concerns regarding drug pricing and ...

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

There's one main way to treat inflammatory bowel disease (IBD): Control inflammation by whipping the immune system into shape, a process that can go haywire or fail to work. But what if the body could ...

Chinese biotech shares are surging this year on growing optimism over innovative cancer treatments being licensed to western ...

Marketers today are operating in an outcome-obsessed world. For mobile app marketers, especially, the smallest screen in the ...

Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) ('Ascentage” or the 'Company”), a global ...

More than 14 million children did not receive a single vaccine last year — about the same number as the year before — according to U.N. health officials. Nine countries accounted for ...